Kevadon - Thalidomide

Estimates come from tallies in Bundesarchiv Koblenz, B142—1826 (Bundesverband der Eltern korpergeschadigter Kinder), and U.S. Food and Drug Administration, New Drug Application 12-611 Kevadon (Thalidomide), volume 1 see also Kirk, Der Contergan-Fall. 

F. Kelsey, Kevadon (thalidomide)—NDA 12-611 Summary Report, 14 November i960, New Drug Application 12611 Kevadon (Thalidomide), v. 1. 

The frequency in Bonn in 1962 was 3.56 per 1000 of all newborn children (200 times the frequency in 1960-61). In Liverpool, the frequency during 1960 and 1961 was lower (0.778 per 1000), but nevertheless considerably higher than in other countries. Cases have been reported from Australia, Scotland, and Sweden (149). The USA was relatively free from this adverse effect, since thalidomide (as Kevadon) failed to pass the Food and Drug Administration because of another adverse effect, namely polyneuropathy (119). 

N-Phthalylglutamic acid imide N-(2,6-Dioxo-3-piperdyl)-phthalimide Talimol Sedalis Kevadon Distavil Thalomid NSC-66847 Chemical/Pharmaceutical/Other Class Thalidomide is a piperidinedione derivative Chemical Formula C13FI10N2O4 Chemical Structure ... 

Tenoretic atenolol, chlorthalidone thalidomide Contergan, Distaval, Kevadon, Thalomid... 

In the United States in 1960, Richardson-Merrell sought marketing approval for thalidomide under the brand name Kevadon. It never reached the market because of the resistance of an FDA medical reviewer. Dr. Francis Kelsey. It is said that she was influenced by her previous experience with the antimalarial drug quinidine, which had teratogenic activity. Her misgivings were based on concerns that peripheral neuritis had been observed in adults. This mixture of concern about safety and previous experience combined to overrule the considerable body of preclinical evidence that the drug was safe. Kelsey... 

---